Volume 33, No 5, May 2023
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 33 Issue 5, May 2023: 337-338
EMP1+ tumor cells drive metastatic relapse
Oscar E. Villarreal , Scott Kopetz*Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Disease relapse after surgical management in patients with early-stage colorectal cancer remains a significant clinical challenge due to its high incidence and lack of efficacious therapeutic interventions. In a recent study, Canellas-Socias et al. demonstrate that EMP1+ tumor cells are responsible for metastatic relapse and can be targeted by neoadjuvant immunotherapy to improve outcomes.